Holen Sie sich die Stockscreener-App
8.36
3.34%
0.27
Schlusskurs vom Vortag:
$8.09
Offen:
$7.98
24-Stunden-Volumen:
891.92K
Relative Volume:
2.17
Marktkapitalisierung:
$413.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-2.6456
EPS:
-3.16
Netto-Cashflow:
$-97.15M
1W Leistung:
-3.80%
1M Leistung:
-6.70%
6M Leistung:
-25.42%
1J Leistung:
-24.00%
1-Tages-Spanne:
$7.97
$8.55
1-Wochen-Bereich:
$7.97
$9.30
52-Wochen-Spanne:
$7.97
$16.88
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
8.36 | 413.13M | 0 | -108.30M | -97.15M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
KALV Stock Touches 52-Week Low at $8.20 Amid Market Challenges - Investing.com Canada
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha
BofA Securities sets price target on Kalvista shares with Buy rating - Investing.com Australia
KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha
KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at Bank of America - MarketBeat
Fmr LLC Increases Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
B of A Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
KalVista appoints new COO amid operational growth By Investing.com - Investing.com Canada
KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer - Marketscreener.com
KalVista appoints new COO amid operational growth - Investing.com
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth - TipRanks
KalVista Pharmaceuticals appoints Jeb Ledell as COO - Seeking Alpha
KalVista Appoints Jeb Ledell as Chief Operating Officer - The Bakersfield Californian
KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges - Investing.com Canada
KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals (NASDAQ:KALV) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
KalVista CEO Benjamin Palleiko sells shares worth $74,363 By Investing.com - Investing.com Canada
KalVista CEO Benjamin Palleiko sells shares worth $74,363 - Investing.com
What is HC Wainwright's Forecast for KALV FY2029 Earnings? - MarketBeat
KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
KalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
KalVista shares hold buy rating on HAE drug outlook - Investing.com
KalVista shares hold buy rating on HAE drug outlook By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals Reports Progress in HAE Treatment - TipRanks
180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Purchased by Readystate Asset Management LP - MarketBeat
KalVista Pharmaceuticals Inc. (KALV) reports earnings - Quartzy
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update - citybiz
Citigroup Inc. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Trading (KALV) With Integrated Risk Controls - Stock Traders Daily
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
KalVista Pharmaceuticals Awards Inducement Stock Options to New Executive Team Members - StockTitan
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - Defense World
Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Rises By 7.3% - MarketBeat
Vestal Point Capital LP Grows Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
KalVista Pharmaceuticals' chief medical officer sells $21,586 in stock - Investing.com India
KalVista Pharmaceuticals' chief medical officer sells $21,586 in stock By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals' chief development officer sells $19,378 in stock - Investing.com India
KalVista Pharmaceuticals' chief development officer sells $19,378 in stock By Investing.com - Investing.com Australia
Insiders At KalVista Pharmaceuticals Sold US$2.5m Of Stock Potentially Indicating Weakness - Simply Wall St
KalVista appoints biotech veteran to board By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors - citybiz
KalVista appoints biotech veteran to board - Investing.com
KalVista Pharmaceuticals Appoints Laurence Reid to Board - TipRanks
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):